Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition

The development of covalent inhibitors against KRAS G12C represents a major milestone in treatment of RAS-driven cancers, especially in non-small cell lung cancer (NSCLC), where KRAS G12C is one of the most common oncogenic driver. Here we investigated if additional KRAS mutations co-occur with KRAS...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaclova, Tereza, Chakraborty, Atanu, Sherwood, James, Ross, Sarah, Carroll, Danielle, Barrett, J. Carl, Downward, Julian, de Bruin, Elza C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854729/
https://www.ncbi.nlm.nih.gov/pubmed/35177674
http://dx.doi.org/10.1038/s41598-022-06369-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854729/
https://www.ncbi.nlm.nih.gov/pubmed/35177674
http://dx.doi.org/10.1038/s41598-022-06369-3

Ejemplares similares